Sort   by:  
 Page size 
MetabolomicsMyeloid PFKFB3-mediated glycolysis promotes kidney fibrosis
Excessive renal fibrosis is a common pathology in progressive chronic kidney diseases. Inflammatory injury and aberrant repair processes contribute to the development of kidney fibrosis. Myeloid cells, particularly monocytes/macrophages, play a crucial role in kidney fibrosis by releasing their proi...
2024-03-12 | MTBLS8278 | MetaboLights
TranscriptomicsExpression data from shoots of rice seedlings after inoculation by Sinorhizobium meliloti 1021
Comparative transcriptome was profiled of rice seedling shoots in responding to live S. meliloti1021(LS) and dead S. meliloti1021 (DS) inoculation. The shoots with LS and DS were collected at 1, 2, 5 and 8 DAI respectively for microarry analysis. A total of 2413 differentially expressed genes (DEGs)...
ORGANISM(S): Oryza sativa Japonica Group 
2016-09-01 | E-GEOD-53535 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 and JL272 to erythromycin treatment
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Campylobacter jejuni 
2013-10-10 | E-GEOD-43026 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni 
2013-10-10 | E-GEOD-43025 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43023 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43024 | biostudies-arrayexpress
ProteomicsHuman,squamous cell lung cancer,LC-MS/MS
We compared the proteome of primary SqCLC tumor tissue between patients with ER (< 10 months) vs. LR (> 30 months) following surgery. iTRAQ-based quantitative 2D LC-MS/MS proteomics were performed on 20 SqCLC tumor samples (10 ER, 10 LR) using a matched pair design in which each ER tumor sample was ...
ORGANISM(S): Homo sapiens (Human) 
2021-09-08 | PXD009383 | Pride
Human Lc-ms/ms Squamous cell lung cancer 
UnknownInterleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice.
Not available
S-EPMC11893787 | biostudies-literature
ProteomicsRACK7 Senses and Fine-Tunes Enhancer Activity
RACK7 senses enhancer activity changes and facilitates their activation
ORGANISM(S): Homo Sapiens 
2025-05-26 | PXD058592 |
ProteomicsTargeting the Galectin-7/TRPM2/Zn2+/DRP-1 Signaling Pathway: A Potential Therapeutic Intervention in the Pathogenesis of SJS/TEN
Targeting the Galectin-7/TRPM2/Zn2+/DRP-1 signaling pathway in keratinocyte presents a prospective therapeutic strategy for mitigating SJS/TEN in the future.
ORGANISM(S): Homo Sapiens 
2024-12-23 | PXD059206 |
Sort   by:  
 Page size